AMPHASTAR PHARMACEUTICALS, INC.

Analyst Reco. Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
42.02 ^USD	+2.21%		+4.61%	-32.06%

Mar. 13	Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Mar. 08	Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60	Mar. 05	MT
BofA Securities Initiates Amphastar Pharmaceuticals at Neutral Rating With $63 Price Target	Nov. 17	MT
Jefferies Reinstates Buy Rating on Amphastar Pharmaceuticals With $70 Price Target	23-07-25	MT
Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $40, Maintains Equal-Weight Rating	23-05-17	MT
Piper Sandler Adjusts Amphastar Pharmaceuticals' Price Target to $40 From $43, Keeps Overweight Rating	22-10-25	MT
Jefferies Assumes Amphastar Pharmaceuticals at Buy with $36 Price Target	22-10-21	MT
Capital One Initiates Amphastar Pharmaceuticals at Overweight Rating With $44 Price Target	22-07-29	MT
Northland Adjusts Price Target on Amphastar Pharmaceuticals to $43 From $33, Keeps Outperform Rating	22-04-11	MT
Piper Sandler Raises Price Target for Amphastar Pharmaceuticals to $47 From $35, Maintains Overweight Rating	22-04-08	MT
Wells Fargo Adjusts Amphastar Pharmaceuticals' Price Target to $32 From $23, Keeps Equalweight Rating	22-03-15	MT
Piper Sandler Adjusts Price Target on Amphastar Pharmaceuticals to $35 From $28, Reiterates Overweight Rating	22-03-11	MT
Piper Sandler Upgrades Amphastar Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $28 From $21	22-01-07	MT
AMPHASTAR PHARMACEUTICALS : Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $20 From $21, Maintains Equal-Weight Rating	21-03-17	MT
AMPHASTAR PHARMACEUTICALS : Wells Fargo Downgrades Amphastar Pharmaceuticals to Equal-Weight From Overweight; Price Target is $21	21-01-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer